Your browser doesn't support javascript.
loading
The landscape of drug sensitivity and resistance in sarcoma.
Al Shihabi, Ahmad; Tebon, Peyton J; Nguyen, Huyen Thi Lam; Chantharasamee, Jomjit; Sartini, Sara; Davarifar, Ardalan; Jensen, Alexandra Y; Diaz-Infante, Miranda; Cox, Hannah; Gonzalez, Alfredo Enrique; Norris, Summer; Sperry, Jantzen; Nakashima, Jonathan; Tavanaie, Nasrin; Winata, Helena; Fitz-Gibbon, Sorel T; Yamaguchi, Takafumi N; Jeong, Jae H; Dry, Sarah; Singh, Arun S; Chmielowski, Bartosz; Crompton, Joseph G; Kalbasi, Anusha K; Eilber, Fritz C; Hornicek, Francis; Bernthal, Nicholas M; Nelson, Scott D; Boutros, Paul C; Federman, Noah C; Yanagawa, Jane; Soragni, Alice.
Affiliation
  • Al Shihabi A; Department of Orthopaedic Surgery, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA; Department of Pathology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA.
  • Tebon PJ; Department of Orthopaedic Surgery, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA; Department of Bioengineering, University of California, Los Angeles, Los Angeles, CA, USA.
  • Nguyen HTL; Department of Orthopaedic Surgery, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA.
  • Chantharasamee J; Division of Hematology-Oncology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA.
  • Sartini S; Department of Orthopaedic Surgery, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA.
  • Davarifar A; Department of Orthopaedic Surgery, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA; Division of Hematology-Oncology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA; Department of Human Genetics, University of
  • Jensen AY; Department of Orthopaedic Surgery, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA.
  • Diaz-Infante M; Department of Orthopaedic Surgery, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA.
  • Cox H; Department of Orthopaedic Surgery, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA.
  • Gonzalez AE; Department of Human Genetics, University of California, Los Angeles, Los Angeles, CA, USA.
  • Norris S; Department of Orthopaedic Surgery, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA.
  • Sperry J; Certis Oncology Solutions, Inc., San Diego, CA, USA.
  • Nakashima J; Certis Oncology Solutions, Inc., San Diego, CA, USA.
  • Tavanaie N; Department of Orthopaedic Surgery, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA.
  • Winata H; Department of Human Genetics, University of California, Los Angeles, Los Angeles, CA, USA.
  • Fitz-Gibbon ST; Department of Human Genetics, University of California, Los Angeles, Los Angeles, CA, USA.
  • Yamaguchi TN; Department of Human Genetics, University of California, Los Angeles, Los Angeles, CA, USA.
  • Jeong JH; Department of Human Genetics, University of California, Los Angeles, Los Angeles, CA, USA.
  • Dry S; Department of Pathology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA.
  • Singh AS; Division of Hematology-Oncology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA.
  • Chmielowski B; Division of Hematology-Oncology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA.
  • Crompton JG; Jonsson Comprehensive Cancer Center, University of California, Los Angeles, Los Angeles, CA, USA; Division of Surgical Oncology David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA.
  • Kalbasi AK; Department of Radiation Oncology, University of California, Los Angeles, Los Angeles, CA, USA.
  • Eilber FC; Division of Surgical Oncology David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA.
  • Hornicek F; Department of Orthopedic Surgery, University of Miami, Miami, FL, USA.
  • Bernthal NM; Department of Orthopaedic Surgery, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA.
  • Nelson SD; Department of Pathology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA.
  • Boutros PC; Department of Human Genetics, University of California, Los Angeles, Los Angeles, CA, USA; Jonsson Comprehensive Cancer Center, University of California, Los Angeles, Los Angeles, CA, USA; Institute for Precision Health, University of California, Los Angeles, Los Angeles, CA, USA; Eli and Edythe Bro
  • Federman NC; Department of Orthopaedic Surgery, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA; Jonsson Comprehensive Cancer Center, University of California, Los Angeles, Los Angeles, CA, USA; Department of Pediatrics, David Geffen School of Medicine, University of
  • Yanagawa J; Department of Surgery, Division of Thoracic Surgery, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA.
  • Soragni A; Department of Orthopaedic Surgery, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA; Jonsson Comprehensive Cancer Center, University of California, Los Angeles, Los Angeles, CA, USA; Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Resear
Cell Stem Cell ; 31(10): 1524-1542.e4, 2024 Oct 03.
Article in En | MEDLINE | ID: mdl-39305899
ABSTRACT
Sarcomas are rare malignancies with over 100 distinct histological subtypes. Their rarity and heterogeneity pose significant challenges to identifying effective therapies, and approved regimens show varied responses. Novel, personalized approaches to therapy are needed to improve patient outcomes. Patient-derived tumor organoids (PDTOs) model tumor behavior across an array of malignancies. We leverage PDTOs to characterize the landscape of drug resistance and sensitivity in sarcoma, collecting 194 specimens from 126 patients spanning 24 distinct sarcoma subtypes. Our high-throughput organoid screening pipeline tested single agents and combinations, with results available within a week from surgery. Drug sensitivity correlated with clinical features such as tumor subtype, treatment history, and disease trajectory. PDTO screening can facilitate optimal drug selection and mirror patient outcomes in sarcoma. We could identify at least one FDA-approved or NCCN-recommended effective regimen for 59% of the specimens, demonstrating the potential of our pipeline to provide actionable treatment information.
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Sarcoma / Drug Resistance, Neoplasm Limits: Adult / Female / Humans / Male / Middle aged Language: En Journal: Cell Stem Cell Year: 2024 Document type: Article Affiliation country: Estados Unidos Country of publication: Estados Unidos
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Sarcoma / Drug Resistance, Neoplasm Limits: Adult / Female / Humans / Male / Middle aged Language: En Journal: Cell Stem Cell Year: 2024 Document type: Article Affiliation country: Estados Unidos Country of publication: Estados Unidos